First indigenous vaccine for infant pneumonia approved

It has been developed by Serum Institute, Pune

Updated - July 16, 2020 10:42 am IST

Published - July 15, 2020 10:55 pm IST - NEW DELHI:

The vaccine is used for active immunisation against pneumonia.

The vaccine is used for active immunisation against pneumonia.

The Drug Controller General of India (DCGI) has approved the first fully indigenously developed conjugate vaccine for pneumonia developed by the Serum Institute of India Pvt. Ltd, Pune.

The Serum Institute first obtained the DGCI approval to conduct Phase I, Phase II and Phase III clinical trials of Pneumococcal Polysaccharide Conjugate Vaccine in India. It has also conducted clinical trials in Gambia, the Health Ministry said in a statement.

Biophore gets DCGI nod to make, export Favipiravir API | The many questions about Favipiravir

“The committee [constituted by the drug regulator]recommended for grant of permission of market authorisation to the said vaccine. Serum Institute of India Pvt. Ltd, Pune has been granted permission to manufacture domestically developed first Pneumococcal Polysaccharide Conjugate Vaccine. Earlier the demand for such vaccine was substantially met by licensed importers since the manufacturers were all based outside India,” the statement added.

This vaccine is used for active immunisation against invasive disease and pneumonia caused by “streptococcus pneumonia” in infants. The vaccine is administered intramuscularly.

Drug launched for moderate COVID-19 cases

According to information on the clinical trials registry, the first phase of the trial was conducted in 2013 in 34 young Indian adults, while the second phase in 114 toddlers of 12-15 months. The third phase of trials was conducted on 448 infants between the age of six to eight weeks old, and this was completed in October last year, as per the registry.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.